(News Bulletin 247) – NFL Biosciences shares rose on Friday morning following the announcement of a stake in GB Holding by businessman Gérard Leduc, a well-known entrepreneur in the pharmaceutical sector.
The title of the biopharmaceutical company, which develops botanical drugs for the treatment of dependencies and addictions, currently takes nearly 3% while the Parisian market is progressing by around 0.7%.
GB Holding exercised 100,000 stock warrants (BSA), bringing its stake to approximately 11.2% of the capital of NFL Biosciences, a level that the businessman has undertaken to maintain for a period of at least nine months.
NFL recalls that Gérard Leduc notably founded, directed and sold Ethypharm, a European pharmaceutical laboratory specializing in pathologies of the central nervous system (CNS) and hospital injectables which had more than 800 employees.
‘Addiction products have always been of great interest to me,’ he explained. “NFL-101, for smoking cessation, is a potentially revolutionary product with an entirely new mechanism of action,” added the entrepreneur.
This capital increase comes as the first results of the two clinical studies on NFL-101 in smoking cessation are expected in the 3rd and 4th quarters of 2023.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
